In this Point/Counterpoint, Drs. Bhat and Punnen argue that active surveillance can be beneficial for patients with intermediate-risk prostate cancer.
Sanoj Punnen, MD, MAS
Advertisement
Articles by Sanoj Punnen, MD, MAS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
What is The State of Radiation Oncology in Head and Neck Cancers?
3
Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC
4
Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial
5